Last updated 2026-08-05
Total raised
—
Stage
Pre-Funding
Founded
2023
Headcount
7
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences
About
To date, many brain conditions are poorly medicated due to limitations in drug-delivery prevent treating patients efficiently. The prominent reason is the Blood Brain Barrier (BBB), which prevents most therapeutic molecules from reaching the brain – and severely limits the arsenal of brain therapeutics.
NucleoTech is developing carriers that deliver a variety of drug-classes across the BBB, including biologics and RNA drugs. The company utilizes the BBBs own transfer mechanisms to allow therapeutic molecules through, by using nanobodies (also called Single Domain Antibodies) as carrier molecules that shuttle therapeutics into the brain by the process of Receptor-Mediated Transcytosis.
Headcount over time
From 6 (2023-05) to 8 (2026-08) · +2 (+33%) · 9 points · source: Finder history + radar grounding
Q&A
- What is NucleoTech's primary focus?
- NucleoTech is developing carriers for effective drug delivery to the brain, specifically addressing the challenge of the Blood Brain Barrier (BBB) which limits therapeutic molecules from reaching the brain.
- What technology does NucleoTech utilize for drug delivery?
- NucleoTech utilizes nanobodies (Single Domain Antibodies) as carrier molecules to shuttle therapeutics into the brain by leveraging the BBB's own transfer mechanisms through Receptor-Mediated Transcytosis.
- What types of drugs can NucleoTech's carriers deliver across the BBB?
- NucleoTech's carriers are designed to deliver a variety of drug classes across the BBB, including biologics and RNA drugs.
- Where is NucleoTech headquartered?
- NucleoTech is headquartered in Rehovot, Israel.
- When was NucleoTech founded?
- NucleoTech was founded in January 2023.
- What is NucleoTech's current employee count?
- NucleoTech has 1-10 employees.
- In which sector does NucleoTech primarily operate?
- NucleoTech's primary sector is Health Tech & Life Sciences, with a focus on Pharma & Medical Biotechnology and Drug Delivery.
Team · 6
Uriah Bekenstein
Founder · Co-Founder & CEO
Adi Koplovitz
Founder · Co-Founder & COO
Naftali Cohen
Founder · Co-Founder & CBO
Shachar Dagan
Head of Research
Tehila Dahan
R&D Manager
Beata Toth-Cohen
Research Adviser
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Tags
nanotechnologybrain-disorderpharmaceuticalsdrug-delivery
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | nucleo-tech.com/cgi-sys/suspendedpage.cgi |
|---|---|
| linkedin.com/company/80056634 |
Identifiers & details
| Legal name | NUCLEOTECH LTD |
|---|---|
| Founded | 2023-1 |
| Employees (exact) | 7 |
| Offices | Englewood |
Radar intelligence
Patents
| EPO | 2 |
|---|
Publications (Crossref)
| Works | 1 |
|---|
Web history (Wayback)
| Domain | nucleo-tech.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516534476 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2022-01-12 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | מורן 16 רחובות |